Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 218

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP)

Open access
Locatelli, F., Covic, A., Eckardt, K.-U., Wiecek, A., Vanholder, R., on behalf of the ERA-EDTA ERBP Advisory Board·2008·Nephrology Dialysis Transplantation

Abstract

Over the last few years, much has been done to develop guidelines on the basis of the strongest possible evidence because this allows an accurate description of the quality and/or degree of uncertainty of the recommendations and provides physicians with a valuable tool for judicious decisions. However, creating and updating evidence-based guidelines is extremely costly, and so the nephrological community has been trying to build up a single set of international guidelines under the aegis of Kidney Disease Improving Global Outcomes (KDIGO) [ 1 ]. As part of this unifying effort, the working group responsible for the 2006 update of the National Kidney Foundation–Kidney Disease Outcome Quality Initiative (NKF-KDOQI) guidelines on anaemia management in patients with chronic kidney disease (CKD) [ 2 ], and the 2007 update on haemoglobin (Hb) targets [ 3 ], included members from Europe, Middle East, Mexico and Canada. However, this international effort may not be correctly perceived by European nephrologists, who sometimes feel that differences in practice patterns make it difficult to apply guidelines developed outside Europe; on the other hand, the latest update of the European Best Practice Guidelines (EBPG) [ 4 ] may appear outdated in some respects. A specially appointed ERA-EDTA Work Group met in Paris to discuss European guideline planning in early January 2008, and agreed that the Association should continue producing and updating guidelines in collaboration with KDIGO [ 5 ]. It also agreed that ERA-EDTA should issue suggestions for clinical practice in areas in which evidence is lacking or weak, which will be presented as ‘position statements’ rather than clinical guidelines [ 5 ]. It was also decided to issue position statements about guidelines (recommendations issued by other bodies, of which the current publication is the first result). Finally, the group opted to change the name EBPG to European Renal Best Practice (ERBP) as a means of acknowledging that, especially in nephrology, it is difficult to generate real ‘guidelines’ because of the lack of sufficient evidence. In this context, and while awaiting the publication of the KDIGO anaemia guidelines possibly in 2011, an ad hoc work group was commissioned by the ERBP Advisory Board to give its opinion on the ‘hot topic’ of Hb targets, including recently raised issues that were not covered by KDOQI in 2006 [ 2 ]. These points are summarized in the present position paper, which is not intended to represent a set of new guidelines as it is not the result of a systematic review of the evidence. In May 2006, the NKF published a revised set of guidelines on managing anaemia in CKD [ 2 ]. The Guideline Committee attempted to integrate new evidence using the 2004 EBPG revision [ 4 ] and the 2000 KDOQI guidelines as a starting point [ 6 ]. The update also involved a systematic review of the evidence based on an extensive search of the literature and the grading of the strength of the evidence, and separated evidence-based guidelines, which could be used to measure clinical performance when appropriate, and clinical practice recommendations primarily based on expert judgement. The result was a solid document summarizing the evidence available up until September 2005. In 1997, the DOQI guidelines on anaemia treatment recommended a target range for haematocrit/Hb of between 33% (Hb 11 g/dl) and 36% (Hb 12 g/dl) [ 7 ]. While waiting for the results of clinical trials concerning complete anaemia correction other than Besarab's study [ 8 ], almost similar recommendations were made in the 2000 update of the KDOQI guidelines [ 6 ] and by EBPG [ 4 ] although no upper limit was defined for the early stages of CKD, while normalization of Hb levels was generally not recommended for patients with diabetes or cardiovascular disease. The 2006 update of the NKF-DOQI guidelines recommended that the target Hb range should generally be ≥11.0 g/dl (lower limit) and stated that there was insufficient evidence to recommend routinely maintaining Hb levels of ≥13.0 g/dl in ESA-treated patients (upper limit) [ 2 ]. At this time, the available findings of randomized clinical trials and meta-analysis [ 9 ] did not suggest any major effect of complete anaemia correction on hard, intermediate or surrogate end-points except the quality of life. Two large-scale randomized trials studying the effect of complete anaemia correction on mortality in patients not on dialysis were published in November 2006 [ 10,11 ]. In the CREATE study [ 10 ], 603 patients with stage 3 and 4 CKD and mild–moderate anaemia were randomly assigned to a target Hb range of 13–15 g/dl (normal range) or 10.5–11.5 g/dl (subnormal range). During the 3 years of the study, the number of cardiovascular events was not significantly different between the two groups (58 versus 47) and there was no difference in the frequency of death from any cause or cardiovascular causes, nor in the incidence of hospitalization. However, p

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/ndt/gfn653

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

Metadata

Authors
Locatelli, F., Covic, A., Eckardt, K.-U., Wiecek, A., Vanholder, R., & on behalf of the ERA-EDTA ERBP Advisory Board
Venue
Nephrology Dialysis Transplantation
Published
2008-11-07
Volume
24
Issue
2
Pages
348-354
ISSN
  • 0931-0509 (ISSN-L)
  • 1460-2385
OpenAlex
W2108858457
Cited by
218
References
2
FWCI
11.07
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.